Partin et al reported predictive information for a male with clinically localized prostate cancer. This can help to predict the extent of disease at radical prostatectomy. The authors are from the Johns Hopkins University, University of Michigan, and Baylor College of Medicine.
Patient selection: male with clinically localized prostate cancer
Parameters:
(1) T code from T1c to T2c
(2) serum PSA in ng/mL
(3) Gleason score
OC = organ confined
ECE = extracapsular extension
SV = seminal vesicle involvement
LN = lymph node metastases
T Code |
PSA |
GS |
OC |
ECE |
SV+ |
LN+ |
T1c |
0 to 2.5 |
2 to 4 |
95 |
5 |
0 |
0 |
|
|
5 or 6 |
90 |
9 |
0 |
0 |
|
|
3+4 |
79 |
17 |
2 |
1 |
|
|
4+3 |
71 |
25 |
2 |
1 |
|
|
8 to 10 |
66 |
28 |
4 |
1 |
|
2.6 to 4 |
2 to 4 |
92 |
8 |
0 |
0 |
|
|
5 or 6 |
84 |
15 |
1 |
0 |
|
|
3+4 |
68 |
27 |
4 |
1 |
|
|
4+3 |
58 |
37 |
4 |
1 |
|
|
8 to 10 |
52 |
40 |
6 |
1 |
|
4.1 to 6 |
2 to 4 |
90 |
10 |
0 |
0 |
|
|
5 or 6 |
89 |
19 |
1 |
0 |
|
|
3+4 |
63 |
32 |
3 |
2 |
|
|
4+3 |
52 |
42 |
3 |
3 |
|
|
8 to 10 |
46 |
45 |
5 |
3 |
|
6.1 to 10 |
2 to 4 |
87 |
13 |
0 |
0 |
|
|
5 or 6 |
75 |
23 |
2 |
0 |
|
|
3+4 |
54 |
36 |
8 |
2 |
|
|
4+3 |
43 |
47 |
8 |
2 |
|
|
8 to 10 |
37 |
48 |
13 |
3 |
|
>10 |
2 to 4 |
80 |
20 |
0 |
0 |
|
|
5 or 6 |
62 |
33 |
4 |
2 |
|
|
3+4 |
37 |
43 |
12 |
8 |
|
|
4+3 |
27 |
51 |
11 |
10 |
|
|
8 to 10 |
22 |
50 |
17 |
11 |
T2a |
0 to 2.5 |
2 to 4 |
91 |
9 |
0 |
0 |
|
|
5 or 6 |
81 |
17 |
1 |
0 |
|
|
3+4 |
64 |
29 |
5 |
2 |
|
|
4+3 |
53 |
40 |
4 |
3 |
|
|
8 to 10 |
47 |
42 |
7 |
3 |
|
2.6 to 4 |
2 to 4 |
85 |
15 |
0 |
0 |
|
|
5 or 6 |
71 |
27 |
2 |
0 |
|
|
3+4 |
50 |
41 |
7 |
2 |
|
|
4+3 |
39 |
52 |
6 |
2 |
|
|
8 to 10 |
33 |
53 |
10 |
3 |
|
4.1 to 6 |
2 to 4 |
81 |
19 |
0 |
0 |
|
|
5 or 6 |
66 |
32 |
1 |
1 |
|
|
3+4 |
44 |
46 |
5 |
4 |
|
|
4+3 |
33 |
56 |
5 |
6 |
|
|
8 to 10 |
28 |
58 |
8 |
6 |
|
6.1 to 10 |
2 to 4 |
76 |
24 |
0 |
0 |
|
|
5 or 6 |
58 |
37 |
4 |
1 |
|
|
3+4 |
35 |
49 |
13 |
3 |
|
|
4+3 |
25 |
58 |
11 |
5 |
|
|
8 to 10 |
21 |
57 |
17 |
5 |
|
>10 |
2 to 4 |
65 |
35 |
0 |
0 |
|
|
5 or 6 |
42 |
47 |
6 |
4 |
|
|
3+4 |
20 |
49 |
16 |
14 |
|
|
4+3 |
14 |
55 |
13 |
18 |
|
|
8 to 10 |
11 |
52 |
19 |
17 |
T2b |
0 to 2.5 |
2 to 4 |
88 |
12 |
0 |
0 |
|
|
5 or 6 |
75 |
22 |
2 |
1 |
|
|
3+4 |
54 |
35 |
6 |
4 |
|
|
4+3 |
43 |
45 |
5 |
6 |
|
|
8 to 10 |
37 |
46 |
9 |
6 |
|
2.6 to 4 |
2 to 4 |
80 |
20 |
0 |
0 |
|
|
5 or 6 |
63 |
34 |
2 |
1 |
|
|
3+4 |
41 |
47 |
9 |
3 |
|
|
4+3 |
30 |
57 |
7 |
4 |
|
|
8 to 10 |
25 |
57 |
12 |
5 |
|
4.1 to 6 |
2 to 4 |
75 |
25 |
0 |
0 |
|
|
5 or 6 |
57 |
39 |
2 |
2 |
|
|
3+4 |
35 |
51 |
7 |
7 |
|
|
4+3 |
25 |
60 |
5 |
10 |
|
|
8 to 10 |
21 |
59 |
9 |
10 |
|
6.1 to 10 |
2 to 4 |
69 |
31 |
0 |
0 |
|
|
5 or 6 |
49 |
44 |
5 |
2 |
|
|
3+4 |
26 |
52 |
16 |
6 |
|
|
4+3 |
19 |
60 |
13 |
8 |
|
|
8 to 10 |
15 |
57 |
19 |
8 |
|
>10 |
2 to 4 |
57 |
43 |
0 |
0 |
|
|
5 or 6 |
33 |
52 |
8 |
8 |
|
|
3+4 |
14 |
47 |
17 |
22 |
|
|
4+3 |
9 |
50 |
13 |
27 |
|
|
8 to 10 |
7 |
46 |
19 |
27 |
T2c |
0 to 2.5 |
2 to 4 |
86 |
14 |
0 |
0 |
|
|
5 or 6 |
73 |
24 |
1 |
1 |
|
|
3+4 |
51 |
36 |
5 |
6 |
|
|
4+3 |
39 |
45 |
5 |
9 |
|
|
8 to 10 |
34 |
47 |
8 |
10 |
|
2.6 to 4 |
2 to 4 |
78 |
22 |
0 |
0 |
|
|
5 or 6 |
61 |
36 |
2 |
1 |
|
|
3+4 |
38 |
48 |
8 |
5 |
|
|
4+3 |
27 |
57 |
6 |
7 |
|
|
8 to 10 |
23 |
57 |
10 |
8 |
|
4.1 to 6 |
2 to 4 |
73 |
27 |
0 |
0 |
|
|
5 or 6 |
55 |
40 |
2 |
3 |
|
|
3+4 |
31 |
50 |
6 |
12 |
|
|
4+3 |
21 |
57 |
4 |
16 |
|
|
8 to 10 |
57 |
7 |
16 |
13 |
|
6.1 to 10 |
2 to 4 |
67 |
33 |
0 |
0 |
|
|
5 or 6 |
46 |
46 |
5 |
3 |
|
|
3+4 |
52 |
13 |
10 |
11 |
|
|
4+3 |
58 |
11 |
13 |
7 |
|
|
8 to 10 |
56 |
16 |
13 |
6 |
|
>10 |
2 to 4 |
54 |
46 |
0 |
0 |
|
|
5 or 6 |
30 |
51 |
6 |
13 |
|
|
3+4 |
11 |
42 |
13 |
33 |
|
|
4+3 |
7 |
43 |
10 |
38 |
|
|
8 to 10 |
6 |
41 |
15 |
38 |
Specialty: Hematology Oncology